Get a Quote

TUCATINIB
CAS NO.: 937263-43-9
Chemical Formula: C26H24N8O2
Molecular Weight: 480.5000
DMF&GMP status: Please contact us for more details.
Description:
Tucatinib is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.

Tucatinbib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
TUCATINIBTABLET;ORAL50MGTUKYSASEAGEN INC
TUCATINIBTABLET;ORAL150MGTUKYSASEAGEN INC
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
745289511/16/2024DSDPU-2788
864808704/12/2031DSDP
945709310/12/2032DPU-2788
969398905/09/2027DPU-2788
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 04/17/2025
ODE-309 04/17/2027